Brief: Ascletis Announces Positive Phase I Clinical Results Of Oral Rdrp Inhibitor Asc10 For Covid-19
12/12/2022 15:59
Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES POSITIVE PHASE I CLINICAL RESULTS OF
ORAL
RDRP INHIBITOR ASC10 FOR COVID-19
* ASCLETIS PHARMA INC - ALL DOSES OF ASC10 INCLUDING 800 MG
TWICE
DAILY WERE SAFE AND WELL TOLERATED IN CHINESE SUBJECTS
Source text for Eikon: ID:nPn26ttwpa
Further company coverage: 1672.HK
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026